tiprankstipranks
Trending News
More News >

Argent Biopharma Announces Cessation of Securities

Story Highlights
  • Argent Biopharma focuses on innovative therapies in the biopharmaceutical sector.
  • The company announced the cessation of certain securities, impacting its capital structure.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Argent Biopharma Announces Cessation of Securities

Don’t Miss TipRanks’ Half-Year Sale

The latest update is out from Argent Biopharma ( (AU:RGT) ).

Argent Biopharma Limited announced the cessation of certain securities, specifically the lapse of 306,000 performance rights and the expiry of 250 Class D performance rights as of April 30, 2025. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s performance and future prospects.

More about Argent Biopharma

Argent Biopharma Limited operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapies. The company is listed on the Australian Securities Exchange (ASX) under the issuer code RGT.

YTD Price Performance: -25.00%

Average Trading Volume: 1,165

Technical Sentiment Signal: Buy

Current Market Cap: $5.15M

See more data about RGT stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1